## Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) (MALS verified)

Catalog # SPD-M162





#### Source

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293).

#### Clone

AM122

### Isotype

Human IgM | Human Kappa

## **Antibody Type**

Recombinant Monoclonal

### Reactivity

Virus

## **Specificity**

This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.

#### Application

Application	Recommended Usage
ELISA	0.6-20 ng/mL

#### **Purity**

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

#### **Purification**

Protein A purified / Protein G purified

#### **Formulation**

Lyophilized from  $0.22~\mu m$  filtered solution in PBS, pH7.4 .

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

#### Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

### **SDS-PAGE**



Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

### **SEC-MALS**



The purity of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) (Cat. No. SPD-M162) is more than 90% and the molecular weight of this protein is around 980-1200 kDa verified by SEC-MALS.

<u>Report</u>




# Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) (MALS verified)

Catalog # SPD-M162






#### **Bioactivity-ELISA**



Immobilized Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) (Cat. No. SPD-M162) at 2  $\mu$ g/mL (100  $\mu$ L/well) can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H1) with a linear range of 0.6-2.4 ng/mL (QC tested).



Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) (Cat. No. SPD-M162) was detected by Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E6) with a half maximal inhibitory concentration (IC50) of 0.88 μg/mL (Routinely tested).

#### Background

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

## **Clinical and Translational Updates**

